| Status: Partially superseded | ||
AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2014. Refer to TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. Epoetin theta (Eporatio®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with symptomatic anaemia associated with chronic renal failure. |
||
|
||
Medicine details |
||
| Medicine name | epoetin theta (Eporatio®) | |
| Formulation | solution for injection | |
| Reference number | 592 | |
| Indication | Treatment of adult patients with symptomatic anaemia associated with chronic renal failure or those with non-myeloid malignancies receiving chemotherapy |
|
| Company | TEVA UK Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Full | |
| Status | Partially superseded | |
| Advice number | 1610 | |
| NMG meeting date | 15/09/2010 | |
| AWMSG meeting date | 13/10/2010 | |
| Ratification by Welsh Government | 17/11/2010 | |
| Date of issue | 18/11/2010 | |
| NICE guidance | TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (external website - opens in new window)
|
|